Avid Bioservices, Inc., a biologics CDMO, has completed construction of cGMP manufacturing suites within its new cell and gene therapy (CGT) development and cGMP manufacturing facility as scheduled. The newly launched suites are currently undergoing final environmental monitoring and performance qualification. With the completion of this latest and final expansion project, Avid estimates that its combined facilities now have a potential total revenue generating capacity of up to approximately $4...